Antidiabetic drug-induced hypoglycemia as a cause of acute medical admissions is more common in Hong Kong (1.7%) than in other countries (0.1 - 0.5%). To determine if this higher incidence may be related to the frequent use of some sulphonylureas, we have studied the overall prescribing patterns in the public sector in 1994 by reviewing the utilization of antidiabetic drugs in the general out-patient/general practice clinics (GOPD) and Hospital Authority public hospitals and affiliated specialist clinics (HA).
The vast majority of patients (90.5%) receiving antidiabetic treatment were taking sulphonylureas and/or metformin, confirming that diabetes mellitus in Hong Kong is predominantly of the noninsulin-dependent type.
The GOPD and the HA each accounted for approximately half of the sulphonylureas (55% vs 45%) and metformin (43% vs 57%) prescribed.
Glibenclamide (84.9% vs 79.1%, 83.7% overall) and gliclazide (12.8% vs 16.6%, 14.5% overall) were the 2 most frequently used sulphonylureas.
Only 9.5% of patients on antidiabetic drugs were receiving insulin and 92% of this was prescribed by the HA.
For comparison, Singapore has a similar prevalence of diabetes mellitus but a much lower incidence of antidiabetic drug-induced hypoglycemia amongst acute medical admissions (0.5%). Tolbutamide was the most frequently used there sulphonylurea (66.6 - 72.2%) with glibenclamide only contributing 20.8 - 28.6%. Thus, the predominant use of glibenclamide in Hong Kong may...
Mots-clés Pascal : Metformine, Glibenclamide, Gliclazide, Tolbutamide, Chimiothérapie, Diabète non insulinodépendant, Traitement, Homme, Hypoglycémiant, Hong Kong, Asie, Singapour, Etude comparative, Toxicité, Hypoglycémie, Pharmacovigilance, Prévalence, Biguanides, Sulfonylurées, Glucose, Epidémiologie, Trouble métabolisme, Endocrinopathie
Mots-clés Pascal anglais : Chemotherapy, Non insulin dependent diabetes, Treatment, Human, Hypoglycemic agent, Hong Kong, Asia, Singapore, Comparative study, Toxicity, Hypoglycemia, Pharmacovigilance, Prevalence, Biguanides, Sulfonylureas, Glucose, Epidemiology, Metabolic disorder, Endocrinopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0075501
Code Inist : 002B02N. Création : 199608.